MyShare
Key factors
| sym | ADMP |
| exch | US |
| MCap | 7253.32K |
| Beta | 1.277 |
| EPS | -10.1 |
| Div date | 0000-00-00 |
Yesterday
| sym | ADMP |
| exch | US |
| close | 0.490 |
| 50 Day MA | 0.904 |
| 200 Day MA | 6.109 |
| 52 Week High | 6.923 |
| 52 Week Low | 0.450 |
| Target Price | 0.42 |
| Market Cap Mln | 7.253 |
Share statistics
| Shares Outstanding | 9359.13K |
| Shares Float | 9145.0K |
| Percent Institutions | 16.58 |
| PercentInsiders | 7.811 |
| SharesShort | 98936 |
| Short Ratio | 0.02 |
| Shares Short Prior Month | 305.91K |
| Short Percent | 1.300 |
Income
| Revenue TTM | 5021.66K |
| Revenue Per Share TTM | 2.222 |
| Quarterly Revenue Growth YOY | -82.5 |
| Gross Profit TTM | -1431.4K |
| EBITDA | -17.7M |
| Diluted Eps TTM | -10.1 |
earning
| Operating Margin TTM | -3.73 |
| Earnings Share | -10.1 |
Dividend
| Dividend Date | 0000-00-00 |
| Last Split Date | 2023-05-22 |
| Last Split Factor | 1:70 |
business
| Enterprise Value Ebitda | -0.78 |
| Enterprise Value Revenue | 15.59 |
| Book Value /share | -4.23 |
| Price Book MRQ | 8.623 |
| Price Sales TTM | 17.64 |
| ReturnOnAssetsTTM | -1.04 |
| ReturnOnEquityTTM | -7.84 |
Sector
| Gic Group | Pharmaceuticals, Biotechnology & Life Sciences |
| Gic Industry | Pharmaceuticals |
| Gic Sector | Health Care |
| Gic Sub Industry | Pharmaceuticals |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
Codes
| ISIN | US00547W2089 |
| CIK | 887247 |
| Code | ADMP |
| CUSIP | 00547W109 |
| Employer Id Number | 82-0429727 |
| CountryISO | US |
| Currency Code | USD |
| Currency Name | US Dollar |
| Exchange | NASDAQ |
| Currency Symbol | $ |
fund
| Type | Common Stock |
| UpdatedAt | 2024-01-07 |
| is Delisted | 1 |
| Delisted Date | 2023-11-09 |
| Home Category | Domestic |
info
| Fiscal Year End | December |
| Full Time Employees | 11.0 |
| IPODate | 1995-08-14 |
| International Domestic | Domestic |
| MostRecent Quarter | 2023-06-30 |
Contact
| Name | Adamis Pharma |
| Address | 11682 El Camino Real, San Diego, CA, United States, 92130 |
| Country Name | USA |
| Phone | 858 997 2400 |
| Web URL | https://www.adamispharmaceuticals.com |
| Logo URL | /img/logos/US/ADMP.png |
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company is headquartered in San Diego, California.